Detection of herpes simplex virus DNA in a cutaneous squamous cell carcinoma by in situ hybridization

1989 ◽  
Vol 281 (5) ◽  
pp. 333-335 ◽  
Author(s):  
A. L. Claudy ◽  
M. C. Chignol ◽  
Y. Chardonnet
Keyword(s):  
Squamous Cell Carcinoma ◽  
In Situ Hybridization ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Simplex Virus

Human papillomavirus and herpes simplex virus in vulvar squamous cell carcinoma in situ

1988 ◽  
Vol 158 (4) ◽  
pp. 862-869 ◽  
Author(s):  
Raymond H. Kaufman ◽  
Jacob Bornstein ◽  
Ervin Adam ◽  
Joyce Burek ◽  
Barbara Tessin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Carcinoma In Situ ◽  
Vulvar Squamous Cell Carcinoma ◽  
Simplex Virus

A comparative review of the potential role of adenovirus and Herpes Simplex Virus in the treatment of advanced squamous cell carcinoma of the head and neck

2009 ◽  
Vol 8 (3) ◽  
pp. 147-155
Author(s):  
Stuart McCaighy
Keyword(s):  
Immune Response ◽  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Phase Iii ◽  
Advanced Squamous Cell Carcinoma ◽  
Simplex Virus

AbstractThe unsatisfactory outcome of patients who receive intensive multimodality treatment for advanced squamous cell carcinoma of the head and neck (SCCHN) has motivated investigators to seek novel treatments to improve survival. Advances in molecular biology has led to the development of cancer gene therapy (CGT) and revived interest in viral vectors as a mechanism. SCCHN is an ideal model for CGT as disease remains locoregional and is amenable to injection of viruses. Adenovirus and Herpes Simplex Virus Type-1 (HSV) are the most studied Oncolytic Viruses (OVs). Both viruses have been shown to select and replicate in tumour cells and demonstrate anti-tumour effect in laboratory studies and clinical trials. Toxicity from OVs is minor and manageable. Different adenoviral mutants have been investigated with mixed responses. One vector, H101, has now been licensed after showing significant tumour regression in conjunction with chemotherapy. HSV has a larger capacity to carry genetic material and with the addition of the granulocyte–macrophage colony–stimulating factor, has the potential to stimulate an immune response systemically and at the site of disease. OVs are limited by the distribution of virus beyond injection site and by pre-existing or rapidly established immune response. Phase III studies are required.

Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma

2006 ◽  
Vol 126 (10) ◽  
pp. 1115-1117 ◽  
Author(s):  
Yasushi Fujimoto ◽  
Terukazu Mizuno ◽  
Saiko Sugiura ◽  
Fumi Goshima ◽  
Shin-Ichi Kohno ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Intratumoral Injection ◽  
Neck Squamous Cell Carcinoma ◽  
Simplex Virus ◽  
Recurrent Head
Sign in / Sign up

Export Citation Format

Share Document